Childhood death rates remain high in some areas of sub-Saharan Africa, despite global reductions in childhood mortality. JAMA Deputy Editor Preeti Malani, MD, MSJ, and author Thomas Lietman, MD, University of California, San Francisco, discuss twice-yearly azithromycin to reduce childhood mortality. Related Content: Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents. Related Content: Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

Following the Dobbs decision, females aged 18-45 years living in states with “trigger laws” that restricted access to abortion reported a greater increase in symptoms of anxiety and depression than those in states without trigger laws. JAMA Associate Editor Donald Goff, MD, speaks with editorialist Julia Steinberg, PhD, associate professor at the School of Public Health at the University of Maryland, about this topic. Related Content: Mental Health Symptoms When Abortion Access Is Restricted Anxiety and Depression Symptoms After the Dobbs Abortion Decision

JAMA Deputy Editor Preeti Malani, MD, MSJ, and author Alexander K. Smith, MD, MS, MPH, University of California, San Francisco, discuss the importance of 2 new palliative care trials that were recently published in JAMA. Related Content: A Tale of 2 Palliative Care Trials Association of Receipt of Palliative Care Interventions With Health Care Use, Quality of Life, and Symptom Burden Among Adults With Chronic Noncancer Illness

Dialysis facilities in the US are financially rewarded for higher rates of home dialysis and kidney transplant, but facilities that serve patients with high social risk might have a harder time meeting these goals. JAMA Associate Editor Karen E. Joynt Maddox, MD, MPH, speaks with Amal N. Trivedi, MD, MPH, of Brown University, about how this plays out under the ESRD Treatment Choices Model. Related Content: Social Risk and Dialysis Facility Performance in the First Year of the ESRD Treatment Choices Model

Alpha-gal syndrome is a food allergy to red meat products that develops after affected individuals are bitten by a tick. JAMA Deputy Editor Kristin Walter, MD, MS, discusses alpha-gal syndrome with author Mariel R. Benjamin, MD, assistant professor in the Division of Allergy and Clinical Immunology at Michigan Medicine. Related Content: What Is Alpha-Gal Syndrome?

The effects of private equity acquisition of US hospitals on the quality of inpatient care and patient outcomes remain largely unknown. JAMA Associate Editor Karen E. Joynt Maddox, MD, MPH, spoke with author Zirui Song, MD, PHD, of Massachusetts General Hospital, about a recent study showing that private equity acquisition was associated with increased hospital-acquired adverse events. Related Content: Changes in Hospital Adverse Events and Patient Outcomes Associated With Private Equity Acquisition

Does reducing dietary sodium benefit patients already taking antihypertensive medication? JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, speaks with author Norrina Allen, PhD, MPH, from Northwestern University, about the effect of dietary sodium on blood pressure. Related Content: Effect of Dietary Sodium on Blood Pressure

Cannabis use is increasing among reproductive-age individuals. JAMA Deputy Editor Linda Brubaker, MD, MS, discusses the associated risks of cannabis exposure during pregnancy with Torri D. Metz, MD, MS, University of Utah Health. Related Content: Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function

Bilateral renal agenesis results in lethal neonatal pulmonary hypoplasia. New evidence from an amnioinfusion trial is available. JAMA Deputy Editor Linda Brubaker, MD, MS, discusses the results from the Renal Anhydramnios Fetal Therapy Trial with Meredith A. Atkinson, MD, MHS, Johns Hopkins University, and Johnathan M. Davis, MD, Tufts University. Related Content: Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis